Menu
Live
Market Overview
Live indices, gainers & losers
Market Pulse
AI-curated live updates
Market Movers
Top gainers & losers by cap
Market Signals
Value, momentum & analyst signals
Smart Money
Insider & congress trades
Hedge Funds
What 63 elite funds bought & sold
52-Week Highs
Stocks breaking out to new highs
52-Week Lows
Beaten-down stocks near support
High Beta
Stocks that move more than the market
Earnings Calendar
Upcoming earnings dates
Daily
Research
Invest
LIVE
Halozyme Therapeutics, Inc.
HALO
NASDAQ·Healthcare·Biotechnology·Mkt cap $9.1B
$78.55
▲ +2.00%
View full research view
Our plain-language verdict, the thesis, risk factors, and what is changing about the business.
View research view52-Week Range
$53.33 - $82.22
P/E
Fwd P/E
Beta
Div Yield
Avg Vol
Shares Out
Mkt Cap
Price action
Price chart
Up 43.0% over the trailing year
Total returns
Price performance
Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.
Why we rate it this way
The thesis at a glance
Bull and bear case · plain-English context across the five lenses we evaluate.
Bull Case
4 reasons
- Proprietary ENHANZE technology with strong patent protection
- Strategic partnerships with top-tier pharmaceutical companies
- Recurring royalty-based revenue model with low incremental costs
- Expanding addressable market across oncology, immunology, and rare diseases
Bear Case
2 risks
- Average volatility.
- Growth premium of 0.3x vs Biotech & Therapeutics peers. Reasonable for this growth rate.
Growth
Strong growth ahead
Expansion of subcutaneous formulations across partner drug portfolios
Value
Growth premium of 0.3x vs Biotech & Therapeutics peers. Reasonable for this growth rate.
Momentum
Strong
+19.4% over 3m
Quality
Excellent
High-growth business (39% revenue growth, 77% gross margin). Profitable with strong growth momentum.
Dividend
None
No dividend
Smart-money signal
Who's buying HALO right now
Insider Form 4s, 13F institutional filings, and Congressional disclosures - at a glance.
Earnings track record
Latest print - beat on both lines
AI-summarized recap of last quarter, plus the surprise on every print.
Next: Aug 4, 2026
MAY 11, 2026
Reported EPS of $1.60 vs $1.54 consensus (+3.9% surprise). Revenue of $376.7M vs $358.6M expected (+5.0%). Beat on both top and bottom lines.
EPS surprise · last 4Q
1 of 1 beats
Q2 26
+3.9%
Next: Aug 4, 2026
Revenue trend · last 8Q
—
—
—
+35%
+41%
+22%
+52%
+42%
Q2 24
Q3 24
Q4 24
Q1 25
Q2 25
Q3 25
Q4 25
Q1 26
$231.4M
$290.1M
$298.0M
$264.9M
$325.7M
$354.3M
$451.8M
$376.7M
Margins · last 8Q
Gross
—
Operating
—
Profit
39.8%
Wall Street consensus
5 analysts · 80% Buy
Live ratings and price targets aggregated across covering analysts.
Buy
80%
Hold
20%
Sell
0%
Median Price Target
$94.00
▲ +19.7% vs $78.55
Latest: HC Wainwright · Jun 16, 2026
3 analysts covering